Replies to post #32957 on Biotech Values

[north40000]

Recall this earlier post re anti-PD-1 antibody of MEDX/ONO:

http://www.investorshub.com/boards/read_msg.asp?message_id=12391903

I believe the Honjo researcher referred to in the WSJ is,
or was, with ONO.

[north40000]

Sekaly et al abstract re PD-1:

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&l...

[jazzbeerman]

yeah, "immunostimulatory" mabs are very interesting. MEDX (& PFE) also have their anti-CTLA-4 mabs, another T cell espresso type mab. The CTLA-4 mabs have shown some darn good melanoma results, with some autoimmune trade-offs.
(and I think you already know my pick for the mab that should fire up T cells most effectively and safely).



j

[jazzbeerman]

speaking of immunostimulatory mabs vs: HIV,

anybody know what became of the ipilimumab phase 1 trial from June 2003?

http://www.medarex.com/cgi-local/item.pl/20030611-555575


tia,

j